PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34206648-2	2021	Human umbilical vein and aortic endothelial cells, pre-treated with prolyl carboxypeptidase-inhibitor compound 8o and/or angiotensin converting enzyme 2 (ACE2)-inhibitor DX600, were incubated with (pyr)-apelin-13 for different time periods.	dx600	170-175	angiotensin converting enzyme 2	Homo sapiens	154-158	
33637588-2	2021	Methods: A series of NOTA-conjugated peptides derived from the known ACE2 inhibitor DX600 were synthesized, with variable linker identity.	dx600	84-89	angiotensin converting enzyme 2	Homo sapiens	69-73	
32852610-11	2020	EPC-EXsACE2 augmented these effects, which were attenuated by ACE2 inhibitor (DX600).	dx600	78-83	angiotensin converting enzyme 2	Homo sapiens	7-11	
24823497-6	2014	The purified human ACE2 converted Abeta43 to Abeta42, and this activity was inhibited by a specific ACE2 inhibitor, DX600.	dx600	116-121	angiotensin converting enzyme 2	Homo sapiens	19-23	
26163449-9	2015	Activation of AT2 with agonist CGP or with ANG II under concomitant AT1 antagonist reduced TNF-alpha-induced ICAM-1 expression, which was reversed by AT2 antagonist PD or ACE2 inhibitor DX600 or knockdown of ACE2 with small interfering RNA.	dx600	186-191	angiotensin converting enzyme 2	Homo sapiens	171-175	
24823497-6	2014	The purified human ACE2 converted Abeta43 to Abeta42, and this activity was inhibited by a specific ACE2 inhibitor, DX600.	dx600	116-121	angiotensin converting enzyme 2	Homo sapiens	100-104	
21880865-3	2011	Whereas recombinant human ACE2 is readily detected in mouse tissues using 1 muM DX600 at pH 7.5, the endogenous ACE2 activity in mouse tissues is barely detectable.	dx600	80-85	angiotensin converting enzyme 2	Homo sapiens	26-30	
23298658-11	2013	DX600, an ACE2 specific inhibitor did not cross-react with ACE.	dx600	0-5	angiotensin converting enzyme 2	Homo sapiens	10-14	
23298658-18	2013	Calu-3 also demonstrated elevated ACE2 enzymatic activity in all three sources and could be inhibited by the ACE2 specific inhibitor DX600 as well as the neutralizing antibodies for the recombinant ACE2.	dx600	133-138	angiotensin converting enzyme 2	Homo sapiens	109-113	
23298658-18	2013	Calu-3 also demonstrated elevated ACE2 enzymatic activity in all three sources and could be inhibited by the ACE2 specific inhibitor DX600 as well as the neutralizing antibodies for the recombinant ACE2.	dx600	133-138	angiotensin converting enzyme 2	Homo sapiens	109-113	
23816468-6	2013	These changes were strikingly prevented by administration of ERK1/2 inhibitor PD98059 (10muM) and JAK/STAT inhibitor WP1066 (5 muM) but were largely aggravated by ACE2 inhibitor DX600 (0.5 muM).	dx600	178-183	angiotensin converting enzyme 2	Homo sapiens	163-167	
21880865-5	2011	ACE2 from all three species could be inhibited by DX600, but the half maximal inhibitory concentration (IC(50)) for human ACE2 was much lower (78-fold) than for rodent ACE2.	dx600	50-55	angiotensin converting enzyme 2	Homo sapiens	0-4	
21880865-5	2011	ACE2 from all three species could be inhibited by DX600, but the half maximal inhibitory concentration (IC(50)) for human ACE2 was much lower (78-fold) than for rodent ACE2.	dx600	50-55	angiotensin converting enzyme 2	Homo sapiens	122-126	
21880865-5	2011	ACE2 from all three species could be inhibited by DX600, but the half maximal inhibitory concentration (IC(50)) for human ACE2 was much lower (78-fold) than for rodent ACE2.	dx600	50-55	angiotensin converting enzyme 2	Homo sapiens	122-126